Drug Trial Radar · NCT03425279
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
Last checked: Nov 20, 2026Latest source record: Sep 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
245
Actual
Start
Feb 15, 2018
Primary completion
Jan 8, 2025
Study completion Jan 8, 2025
Sponsor
- Lead sponsor
- BioAtla, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the safety and efficacy of mecbotamab vedotin (BA3011) in solid tumors.
Conditions
- Undifferentiated Pleomorphic Sarcoma
- Myxofibrosarcoma
Interventions
CAB-AXL-ADCBiological
Conditionally active biologic anti-AXL antibody drug conjugate
PD-1 inhibitorBiological
PD-1 inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Safety ProfileTime frame: Up to 24 months
- Phase 1: Safety ProfileTime frame: Up to 24 months
- Phase 1 and 2: Safety ProfileTime frame: Up to 24 months
- Phase 2: Confirmed overall response rate (ORR) per RECIST v1.1Time frame: Up to 24 months
Locations
40 sites in 3 countries. Site status is shown where the registry gives one.
The University of Arizona Cancer Center
Tucson, Arizona
Children's Hospital Los Angeles
Los Angeles, California
USC Norris Comprehensive Cancer Center
Los Angeles, California
Tower Hematology Oncology Medical Group
Los Angeles, California
Precision NextGen Oncology
Los Angeles, California
UCSF Medical Center - Cancer Immunotherapy Clinic (CIC)
San Francisco, California
University of Colorado
Aurora, Colorado
Sarah Cannon Research Institute at Health One
Denver, Colorado
Children's Research Institute
Washington D.C., District of Columbia
Moffitt Cancer Center
Tampa, Florida
Northwestern University
Chicago, Illinois
Norton Cancer Institute
Louisville, Kentucky
Massachusetts General Hospital
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri
Comprehensive Cancer Center of Nevada
Las Vegas, Nevada
Roswell Park Cancer Institute
Buffalo, New York
Columbia University
New York, New York
Memorial Sloan Kettering
New York, New York
Duke Cancer Institute
Durham, North Carolina
Wake Forest Baptist Health
Winston-Salem, North Carolina
The Christ Hospital
Cincinnati, Ohio
University Hospitals Seidman Cancer Center
Cleveland, Ohio
Nationwide Children's Hospital
Columbus, Ohio
The Ohio State University Wexner Medical Center
Columbus, Ohio
Oregon Health & Science University
Portland, Oregon
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Abramson Cancer Center at Pennsylvania Hospital
Philadelphia, Pennsylvania
Tennessee Oncology
Nashville, Tennessee
Vanderbilt Ingram Cancer Center
Nashville, Tennessee
Mary Crowley Cancer Research
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
University of Utah - Huntsman Cancer Institute
Salt Lake City, Utah
Seattle Cancer Care Alliance
Seattle, Washington
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin
Prince of Wales Hospital
Hong Kong, Hong Kong
Queen Mary Hospital
Hong Kong, Hong Kong
National Cheng Kung University Hospital
Tainan, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Chang Gung Memorial Hospital
Taoyuan, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.